Drug Trial Radar · NCT03795974
Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy
Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Actual
Start
Jul 23, 2017
Primary completion
Oct 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Tehran University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hormozgan University of Medical Sciences
- First posted
- Jan 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cerebral palsy(CP) consisted of a group of developmental disability in the field of motor function and is one of the major problems of pediatric neurology and at the present time there is no standard curative medical or surgical treatment for it .Stem cell therapy is one of a new and hopeful therapeutic methods of therapy for CP .This double blind study designed for the evaluation of safety and therapeutic effects of intrathecal hematopoietic and mesenchymal stem cells derived from allogenic umbilical cord in change and probable improvement of developmental functions of spastic CP participants between 4-14 years old and comparing with control group of CP participants without cell therapy . 108 cases recruited and randomly divided to 3 groups of 36 cases : hematopoietic stem cells derived from allogenic umbilical cord , Mesenchymal cells derived from allogenic umbilical cord and control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators . Developmental functions and spasticity evaluated before intervention and will be done 1 , 3 , 6 and 12 months after injection . During this period neuro rehabilitation will be continued . Brain neuroimaging were done at the recruitment time and will be repeated after 12 months .
Conditions
- Cerebral Palsy, Spastic
Interventions
MNCBiological
Hematopoietic stem cells derived from allogenic umbilical cord
MSCBiological
Mesenchymal cells derived from allogenic umbilical cord
ControlProcedure
control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: Baseline
- Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 3
- Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 6
- Change from baseline Gross Motor Function Classification System (GMFCS)Time frame: "month" 12
- Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: Baseline
- Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 1
- Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 3
- Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 6
- Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)Time frame: "month" 12
- Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: Baseline
- Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 3
- Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 6
- Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)Time frame: "month" 12
- Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: Baseline
- Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: "month" 6
- Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)Time frame: "month" 12
- Change from baseline Modified Ashworth scaleTime frame: Baseline
- Change from baseline Modified Ashworth scaleTime frame: "month" 1
- Change from baseline Modified Ashworth scaleTime frame: "month" 3
- Change from baseline Modified Ashworth scaleTime frame: "month" 6
- Change from baseline Modified Ashworth scaleTime frame: "month" 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Tehran University of Medical Sciences , Growth and Development Research Center- Children's Medical Center
Tehran, Iran
Tehran University of Medical Sciences Chidren's Medical Center Radiology Department
Tehran, Iran
Tehran University of Medical Sciences, Department of Pediatric Neurology , Children's Medical Center
Tehran, Iran
ROYAN Stem Cell Technology Co
Tehran, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.